Maen Abdelrahim, Professor of Medicine, Chief of GI Medical Oncology, Medical Director of CCAT Phase I Center, Houston Methodist, shared a post on LinkedIn:
“Great news for our patients with the devastating disease of pancreatic cancer. Daraxonrasib is now FDA approved for expanded access.”
Other articles featuring Maen Abdelrahim.